

מכון ויצמן למדע

WEIZMANN INSTITUTE OF SCIENCE



Potential roles of gut microbiome and metabolites in modulating ALS in mice

Document Version:

Accepted author manuscript (peer-reviewed)

Citation for published version:

Blacher, E, Bashiardes, S, Shapiro, H, Rothschild, D, Mor, U, Dori-Bachash, M, Kleimeyer, C, Moresi, C, Harnik, Y, Zur, M, Zabari, M, Brik, RB-Z, Kviatcovsky, D, Zmora, N, Cohen, Y, Bar, N, Levi, I, Amar, N, Mehlman, T, Brandis, A, Biton, I, Kuperman, Y, Tsoory, M, Alfahel, L, Harmelin, A, Schwartz, M, Israelson, A, Arike, L, Johansson, MEV, Hansson, GC, Gotkine, M, Segal, E & Elinav, E 2019, 'Potential roles of gut microbiome and metabolites in modulating ALS in mice', *Nature*, vol. 572, no. 7770, pp. 474-480.
<https://doi.org/10.1038/s41586-019-1443-5>

Total number of authors:

33

Digital Object Identifier (DOI):

[10.1038/s41586-019-1443-5](https://doi.org/10.1038/s41586-019-1443-5)

Published In:

Nature

License:

Other

General rights

@ 2020 This manuscript version is made available under the above license via The Weizmann Institute of Science Open Access Collection is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognize and abide by the legal requirements associated with these rights.

How does open access to this work benefit you?

Let us know @ library@weizmann.ac.il

Take down policy

The Weizmann Institute of Science has made every reasonable effort to ensure that Weizmann Institute of Science content complies with copyright restrictions. If you believe that the public display of this file breaches copyright please contact library@weizmann.ac.il providing details, and we will remove access to the work immediately and investigate your claim.

1 Potential roles of gut microbiome & metabolites in modulation of murine ALS

2
3 Eran Blacher^{1,*}, Stavros Bashiardes^{1,*}, Hagit Shapiro^{1,*}, Daphna Rothschild^{2,3,*}, Uria Mor¹, Mally Dori-
4 Bachash¹, Christian Kleimeyer¹, Claudia Moresi¹, Yotam Harnik¹, Maya Zur¹, Michal Zabari⁴, Rotem Ben-
5 Zeev Brik¹, Denise Kviatcovsky¹, Niv Zmora¹, Yotam Cohen¹, Noam Bar^{2,3}, Izhak Levi^{2,3}, Nira Amar¹, Tevie
6 Mehlman⁵, Alexander Brandis⁵, Inbal Biton⁶, Yael Kuperman⁶, Michael Tsoory⁶, Leenor Alfahel⁷, Alon
7 Harmelin⁶, Michal Schwartz⁸, Adrian Israelson⁷, Liisa Arike⁹, Malin E.V. Johansson⁹, Gunnar C. Hansson⁹,
8 Marc Gotkine^{4,#}, Eran Segal^{2,3,#}, Eran Elinav^{1,10,11,#}

9
10 ¹Immunology Department, Weizmann Institute of Science, Rehovot, 7610001, Israel
11 ²Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, 7610001, Israel
12 ³Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot,
13 7610001, Israel
14 ⁴ Neuromuscular/EMG service and ALS/Motor Neuron Disease Clinic, Department of Neurology,
15 The Agnes Ginges Center for Human Neurogenetics, Hadassah-Hebrew University Medical Center,
16 Jerusalem, 9112001, Israel
17 ⁵Department of Biological Services, Weizmann Institute of Science, Rehovot, 7610001, Israel
18 ⁶Department of Veterinary Resources, Weizmann Institute of Science, Rehovot, 7610001, Israel.
19 ⁷Department of Physiology and Cell Biology, Ben-Gurion University of the Negev, 84105, Beer Sheva, Israel
20 ⁸Department of Neurobiology, Weizmann Institute of Science, Rehovot, 7610001, Israel
21 ⁹Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Gothenburg, Sweden
22 ¹⁰ Division of Cancer-Microbiome Research, DKFZ, Heidelberg, Germany

23 ¹¹Lead contact

24 * Equal contribution

25 # Joint supervision

26
27 *All correspondence to:

28 Marc Gotkine, M.D.
29 Neuromuscular/EMG service and ALS/Motor Neuron Disease Clinic
30 Hadassah - Hebrew University Medical Center
31 Jerusalem, Israel, 9112001
32 (02) 6777741 (phone)
33 marc@gotkine.com

34
35 Eran Segal, Ph.D.
36 Department of Computer Science and Applied Mathematics
37 Weizmann Institute of Science,
38 100 Herzl Street,
39 Rehovot, Israel, 7610001
40 (08) 934-4282 (phone)
41 eran.segal@weizmann.ac.il

42
43 Eran Elinav, M.D., Ph.D.
44 Immunology Department,
45 Weizmann Institute of Science,
46 100 Herzl Street,
47 Rehovot, Israel, 7610001
48 +972-8-934-4014 (phone)
49 eran.elinav@weizmann.ac.il
50 & Division of Cancer-Microbiome Research
51 DKFZ, Heidelberg, Germany
52 e.elinav@dkfz-heidelberg.de

53
54 **Keywords:** Amyotrophic lateral sclerosis; ALS; Motor neuron disease; SOD1; microbiome; Akkermansia;
55 Nicotinamide

56

57 **Summary**

58 Amyotrophic Lateral Sclerosis (ALS) is a genetically-driven neurodegenerative disorder, whose clinical
59 manifestations may be influenced by unknown environmental factors. We demonstrate that ALS-prone
60 SOD1-Tg mice feature a pre-symptomatic, vivarium-dependent dysbiosis and altered metabolite
61 configuration, coupled with an exacerbated disease in germ-free or wide-spectrum antibiotic treatment
62 conditions. We correlate 11 distinct commensals at our vivarium with mouse-ALS severity, and exemplify
63 by their individual supplementation into antibiotic-treated SOD1-Tg mice that *Akkermansia muciniphila*
64 (AM) ameliorates & *Ruminococcus torques* & *Parabacteroides distasonis* exacerbate mouse-ALS
65 symptoms. Furthermore, AM-administered SOD1-Tg mice feature a CNS accumulation of AM-associated
66 nicotinamide, which improves, upon systemic supplementation, motor symptoms and spinal-cord gene
67 expression patterns in SOD-1-Tg mice. In humans, we identify distinct microbiome/metabolite
68 configurations, including impaired systemic & cerebrospinal-fluid nicotinamide levels, in a small
69 preliminary study assessing ALS patients versus household-controls. Together, we suggest that
70 environmentally-driven microbiome-brain interactions may modulate murine ALS, and call for similar
71 investigations in human ALS.

72

73 **Introduction**

74 Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized by premature death of
75 motor neurons and an average survival rate of 3-5 years from diagnosis¹. Extensive efforts are being made
76 to develop ALS-specific drugs, with only riluzole² and edaravone³ showing modest efficacy. Environmental
77 factors have been postulated to modify ALS disease course⁴, and may include circulating small molecular-
78 weight metabolites originating from the gastrointestinal (GI) tract and permeating the brain-blood barrier
79 (BBB), where they can modulate metabolic, transcriptional and epigenetic programs in neurons and in
80 other resident cells⁴. However, the causative role of such environmental factors in ALS or other CNS
81 pathologies is only beginning to be unraveled⁵.

82 The gut microbiome is an putative source of these potentially CNS disease-modifying bioactive
83 metabolites, and has been recently suggested to contribute to the pathogenesis of neurological
84 disorders^{6,7} by impacting neuronal transmission, synaptic plasticity, myelination and complex host
85 behaviors⁸⁻¹⁰. Several observations suggest that host-gut microbiome interface may be altered in murine
86 ALS models⁸⁻¹⁰, including an impaired gut barrier function and a dysbiotic microbiome configuration which
87 was partially corrected by butyrate supplementation¹¹. Stool 16S rDNA analysis of ALS patients yielded
88 conflicting results, with one study noting a dysbiosis in 6 ALS patients compared to 5 healthy controls¹²,
89 while another showing no significant differences between 25 ALS patients and 32 healthy controls¹³. No
90 direct functional microbiome investigation has been performed to date in this setting. In this study, we
91 utilized mice and a preliminary human study in functionally assessing potential modulatory microbiome
92 involvement in ALS.

93

94 **Results**

95 **An altered gut microbiome exacerbates murine ALS symptoms**

96 To assess the role of the gut microbiome in ALS we used the mSOD1 G93A (herein "SOD1-Tg") ALS mouse
97 model. First, we depleted the microbiome of male and female SOD1-Tg or littermate controls by
98 administering broad-spectrum antibiotics (Abx) at the age of 40 days (**Extended Data Fig. 1a**). Motor
99 abilities were quantified using the rotarod locomotor test¹⁴, hanging-wire grip test¹⁵ and neurological

100 scoring¹⁶. Throughout the project, key repeat experiments were independently scored by two blinded
101 researchers. Surprisingly, Abx treatment was associated with a significant and substantial exacerbation of
102 motor abnormalities throughout ALS progression, compared to the water-treated SOD1-Tg group. Both
103 the pooled results (N=15-30 mice per group, **Fig. 1a-c**) and independent results of each of the repeats ((N=
104 5-10 mice in each group of each repeat, three independent repeats, **Supporting Information Fig. 1**)
105 demonstrated worsened results in the rotarod locomotor test (**Fig. 1a, Supporting Information Fig. 1a,**
106 **1d and 1g**), the hanging-wire grip test (**Fig. 1b, Supporting Information Fig. 1b, 1e and 1h**) and
107 neurological scoring (**Fig. 1c, Supporting Information Fig. 1c, 1f and 1i**). Notably, Abx treatment did not
108 affect rotarod or grip test performances in WT littermate controls at our vivarium, as compared to non-
109 Abx-treated WT mice (**Fig. 1a-c and Supporting Information Fig. 1a-i**). A linear regression analysis further
110 supported the negative effect of Abx treatment on these neuropathological measurements (**Extended**
111 **Data Fig. 1b-d**).

112 In agreement with these findings, spinal cord histopathological analysis (using luxol fast-blue staining) at
113 day 140 revealed a significant reduction in motor neuron cell counts in Abx-treated compared to water-
114 treated SOD1-Tg mice (**Extended Data Fig. 1e-f**), suggesting an increased motor neuron cell-death
115 following chronic Abx exposure. Moreover, T₂-weighted magnetic resonance imaging (MRI) of the murine
116 brain stem in areas known to degenerate in the SOD1-Tg model¹⁷ (**Extended Data Fig. 1g**) demonstrated
117 a prolonged T₂ relaxation time Abx-treated SOD1-Tg mice (**Extended Data Fig. 1h-o**), indicative of higher
118 levels of free water, enhanced brain atrophy and neurodegeneration¹⁸. Automated home-cage
119 locomotion system revealed a significant reduction ($p=0.03$) in the activity of Abx-treated SOD1-Tg mice
120 on day 100 compared to water-treated SOD1-Tg controls (**Extended Data Fig. 1p**). Abx-induced
121 aggravation in motor function of SOD1-Tg mice was not associated with alterations of the main immune
122 cell sub-populations in spinal cord, small intestine or colon lamina propria, compared to water-treated
123 SOD1-Tg mice (**Supporting Information Fig. 1j-o**), suggesting that the Abx-associated phenotypic
124 differences were not immune-mediated.

125 Importantly, rederivation attempts of SOD1-Tg mice into the germ-free setting were associated with high-
126 mortality rates of SOD1-Tg but not of WT littermate controls (failed rederivation attempts of 30 pregnant
127 dams over a period of 18 months). Once rederivation succeeded, GF SOD1-Tg mice featured significantly
128 enhanced mortality as compared to GF WT littermates or to colonized SOD1-Tg mice (**Fig. 1d**, pooled
129 results, N=9-22 mice per group, **Supporting Information Fig. 1p-q**, two independent repeats, N=5-13 per
130 group), which persisted even when GF mice were spontaneously colonized at day 115, suggesting that
131 microbial drivers impact ALS progression at an earlier disease stage. Collectively, these results indicated a
132 potential detrimental effect of Abx-mediated microbiome alteration (or its absence in GF mice) at our
133 vivarium, on ALS manifestation in SOD1-Tg mice, suggesting that a locally dysbiotic gut microbiome
134 configuration may modulate disease progression in this model.

135

136 **SOD1-Tg mice develop a vivarium-dependent pre-clinical dysbiosis**

137 These suggested microbial-mediated effects on ALS neuropathology presented an opportunity to identify
138 locally-prevalent commensal strains potentially modulating ALS course. Indeed, assessment of fecal
139 microbiome composition and function by 16s rDNA sequencing in SOD1-Tg and WT littermate controls at
140 our facility indicated an early and significant microbiome compositional difference that persisted during
141 disease course (**Fig. 2a-c, Extended Data Fig. 2a-m**). Moreover, the total number of observed genera
142 (alpha diversity) was higher in the SOD1-Tg stool at all time-points (**Extended Data Fig. 2n**). However, total

143 fecal bacterial load did not vary between SOD1-Tg and WT controls (**Extended Data Fig. 2o**). Moreover,
144 even the gut microbiome configuration of Abx-treated SOD1-Tg and their WT littermate controls at our
145 vivarium yielded significantly differential microbiome compositions (**Supporting Information Fig. 2**)
146 Importantly, spontaneous colonization of GF SOD1-Tg and WT littermates at our vivarium resulted in de-
147 novo dysbiosis (**Extended Data Fig. 3**), while these facility-dependent dysbiotic differences were not
148 observed in a second non-barrier (non-SPF) vivarium featuring a near-absence of Akkermansia,
149 Parabacteroides, Erysipelotrichaceae and Helicobacteraceae (**Supporting Information Fig. 3 and**
150 **Supporting table 1**). Overall, these facility-dependent changes suggested that a combination of murine-
151 ALS genetic susceptibility, coupled with a locally-prevalent commensal signature drive early pre-clinical
152 dysbiosis possibly contributing to ALS modulation.

153 Likewise, when measured by fecal shotgun metagenomic sequencing, significant differences were noted
154 in the microbiome composition of SOD1-Tg mice compared with littermate controls (**Fig. 2d and Extended**
155 **Data Fig. 3a-b, Extended Data Fig. 4a-n**). Functionally, SOD1-Tg and WT fecal bacterial metagenomes
156 clustered separately with respect to microbial genes (for PC1: day 40, $p=0.0002$, day 60, $p=0.0002$, day
157 80, $p=0.0005$, day 100, $p=0.0005$, KEGG orthology, KO, **Fig. 2e**), including a marked reduction in
158 representation of genes encoding enzymes participating in tryptophan metabolism (**Extended Data Fig.**
159 **4o-p**) and substantial alterations in those of nicotinamide and nicotinate metabolism (**Extended Data Fig.**
160 **4q**). A detailed metabolic assessment at the pre-clinical day 60 found no significant changes in food and
161 water intake, respiratory exchange ratio, oxygen consumption, locomotion, and heat production
162 (**Supporting Information Fig. 4**).

163 Collectively, these results demonstrated that single-genotype-housed SOD1-Tg mice diverge in their gut
164 microbial composition and function from their WT littermate configuration at our vivarium, even before
165 the appearance of motor neuron dysfunction.

166

167 **Commensal microbe contribution to ALS exacerbation**

168 To determine whether these ALS-associated microbiome changes feature a causal contribution to disease
169 features, we tested 11 strains, including *Eggerthella lenta*, *Coprobacillus cateniformis*, *Parabacteroides*
170 *goldsteinii*, *Lactobacillus murinus*, *Parabacteroides distasonis*, *Lactobacillus gasseri*, *Prevotella*
171 *melaninogenica*, *Eisenbergiella tayi* (member of the Lachnospiraceae family), *Subdoligranulum variabile*,
172 *Ruminococcus torques* and *Akkermansia muciniphila*, all suggested by our composite 16S rDNA and
173 shotgun metagenomic analysis to be correlated with severity of ALS progression in the SOD1-Tg model at
174 our vivarium (**Extended Data Fig. 2 and 4**). We mono-inoculated anaerobic cultures of each of the above
175 strains (stationary phase O.D.=0.4-0.7) into Abx pre-treated SOD1-Tg and WT mice, by repeated oral
176 administration at 6 day-intervals for a total of 15 treatments. Most of the indicated bacteria did not affect
177 ALS symptoms (**Extended Data Fig. 5**). Supplementation of Abx-treated SOD1-Tg mice with
178 *Parabacteroides distasonis* (PD, **Extended Data Fig. 5**) and *Ruminococcus torques* (RT, **Extended Data Fig.**
179 **6 and Supporting Information Fig. 5** for pooled and 4 independent repeats) exacerbated disease
180 progression, while *Lactobacillus gasseri* and *Prevotella melaninogenica* treatments (LG and PM,
181 respectively) showed disease-promoting effects in some, but not all, of the behavioral tests (**Extended**
182 **Data Fig. 5**). Of note, none of the tested 11 bacterial strains affected motor abilities in WT animals
183 (**Extended Data Fig. 5g-i** for 9 tested bacterial strains, and **Extended Data Fig. 6 and Supporting**
184 **Information Fig. 5** for RT) and all resulted in a distinct microbiome composition in SOD1-Tg mice

185 **(Supporting Information Fig. 6)**. Taken together, these results suggest that several commensals might
186 contribute to motor neuron degeneration in the SOD1-Tg ALS mouse model.

187

188 **AM colonization ameliorates murine ALS and prolongs survival**

189 One of the differentially altered species in SOD1-Tg mice at our vivarium was *Akkermansia muciniphila*
190 (AM), with both 16S rDNA **(Extended Data Fig. 2c)** and shotgun metagenomic sequencing **(Extended Data**
191 **Fig. 4b and Fig. 3a)** demonstrating that it gradually reduced in its abundance as disease progressed in
192 SOD1-Tg mice, as compared to the WT littermate microbiome. Time-dependent AM reduction in SOD1-
193 Tg mice was validated using AM-specific qPCR **(Fig. 3b)**. In contrast to all of the other tested strains,
194 treatment of Abx pre-treated SOD1-Tg and WT mice with an anaerobically mono-cultured AM strain (BAA-
195 835, O.D. =0.7, stationary phase), was associated with improved motor function in AM-treated SOD1-Tg
196 mice as quantified by the rotarod, grip and neurological scoring tests and assessed in pooled samples
197 (N=34-62 mice per group, **Fig. 3c-e**) or independently from 6 repeats (N= 5-25 mice in each group of each
198 repeat, **Extended Data Fig. 5a-c and Supporting Information Fig. 7)**. This AM-mediated functional
199 improvement was accompanied by a higher motor neuron survival in the AM-treated SOD1-Tg spinal
200 cords, as compared to vehicle-treated Abx-pre-treated SOD1-Tg mice **(Extended Data Fig. 7a-b,**
201 $p=0.0041$). Importantly, AM treatment significantly and substantially prolonged the life-span of SOD1-Tg
202 mice compared to vehicle-treated mice or to SOD1-Tg mice treated with other commensal microbiome
203 species serving as bacterial controls **(Fig. 3f)**. AM treatment reduced brain atrophy at day 140, as indicated
204 by MRI **(Extended Data Fig. 7c-f)**. No differences in gut barrier function, as measured by systemic FITC-
205 dextran influx, were found at day 120 between AM-, PBS- and other microbial treated SOD1-Tg and WT
206 mice **(Extended Data Fig. 7g)**. The microbiome metagenome of AM-treated SOD1-Tg mice clustered
207 differently than that of PBS-treated SOD1-Tg controls **(Extended Data Fig. 7h)**. As expected, AM relative
208 abundance was significantly increased in stool samples of AM-treated as compared to vehicle-treated
209 SOD1-Tg mice **(Extended Data Fig. 7i)**. In contrast, WT mice harboring high and stable indigenous AM
210 levels at our vivarium featured competitive exclusion of exogenously-administered AM whose levels rose
211 only upon prolonged administration **(Extended Data Fig. 7j)**. Moreover, AM was found to colonize more
212 broadly and efficiently in different regions of the SOD1-Tg GI tract comparing to the WT GI tract **(Extended**
213 **Data Fig. 7k-l)**. Consequently, AM supplementation following Abx treatment altered the microbiome
214 composition of both WT and SOD1-Tg mice in distinct manners **(Extended Data Fig. 7m-n)**. Similarly,
215 mono-colonization of Abx-pretreated SOD1-Tg and WT littermates with another strain of AM (ATCC 2869)
216 induced a significant improvement in motor abilities **(Extended Data Fig. 7o-q)**. Histopathological analysis
217 of distal colon mucus of AM- or PBS-treated SOD1-Tg at day 140 demonstrated an intact inner mucus layer
218 mucus in both AM supplemented and PBS-treated SOD1-Tg mice **(Extended Data Fig. 8a)**, with only AM-
219 treated SOD1-Tg mice featuring penetrating bacteria in the inner mucus and in rarely in the crypts
220 **(Extended Data Fig. 8b, white arrows)**. A proteomic analysis did not feature significant differences in
221 mucus components levels in AM-supplemented mice **(Extended Data Fig. 8c-j)**. Collectively, assessment
222 of multiple differentially expressed gut commensals by their mono-inoculation into SOD1-Tg mice
223 identified selected commensals that adversely (PD, RT, and potentially LG and PM) or favorably (AM)
224 modulate murine-ALS disease course and severity.

225

226

227

228 **AM attenuates murine ALS by systemically elevating Nicotinamide levels**

229 Given the remoteness of the gut microbiome from the CNS disease site, we hypothesized that a potential
230 systemic influx of microbiome-regulated metabolites may impact motor neuron susceptibility in SOD1-Tg
231 mice by translocating to the CNS^{19,20}. To this aim, we utilized untargeted metabolomic profiling to identify
232 candidate microbiome-dependent molecules differentially abundant in sera of AM-supplemented and
233 vehicle controls, during the early stage of ALS (day 100). Out of 711 serum metabolites identified in SOD1-
234 Tg mice, 84 metabolites were significantly altered by AM supplementation, out of which 51 were elevated
235 by AM treatment (**Fig. 4a and Extended Data Fig. 9a-c**). Of these, the biosynthetic genes (nucleotide
236 sequences, KEGG database) of only 6 metabolites were aligned to our metagenomic index, with two
237 metabolites, Nicotinamide and Phenol sulfate, featuring the highest metagenomic probabilities to be
238 synthesized by the WT microbiome over the SOD1-Tg microbiome at our vivarium (**Extended Data Fig.**
239 **9d**). Administration of Phenol sulfate to SOD1-Tg mice, using subcutaneously implanted slow-release mini
240 osmotic pumps did not affect ALS symptoms *in vivo* (**Extended Data Fig. 9e-g**).

241 We next focused on NAM, given marked alterations in the metagenomic NAM biosynthetic pathway
242 between SOD1-Tg and WT controls (**Fig. Extended Data Fig. 4q**), enrichment in serum levels of NAM
243 biosynthetic intermediates upon AM supplementation (**Fig. 4b**), reduced abundance of genes of the gut
244 microbiome-derived tryptophan metabolizing pathway which may be involved in generation of NAM²¹ in
245 naïve SOD1-Tg mice (**Fig. Extended Data Fig. 4o-p**), and altered metabolites of the tryptophan pathway
246 upon Abx treatment or AM supplementation (**Extended Data Fig. 9h-i**). We first measured NAM levels in
247 anaerobically-grown AM and control commensal isolates, using targeted metabolomics and found
248 significantly higher levels of NAM in the medium of AM cultures, compared to heat-killed AM or from
249 other commensal isolates (**Fig. 4c**). *In vivo*, CSF NAM levels were significantly higher in both AM-treated
250 SOD1-Tg and WT mice already at age 100 days (early-stage disease, **Fig. 4d**). During advanced stages of
251 the disease (day 140), CSF NAM levels were significantly higher in AM-treated SOD1-Tg mice but not in
252 AM-treated WT mice as compared to untreated controls (**Extended Data Fig. 9j**), potentially reflecting gut
253 colonization stability differences between WT and SOD1-Tg mice (**Extended Data Fig. 7i-n**). Importantly,
254 8 out of the 10 AM genome-related genes that encode enzymes participating in NAM metabolism, were
255 significantly enriched in AM-treated SOD1-Tg mice compared to vehicle-treated SOD1-Tg mice (**Extended**
256 **Data Fig. 9a and Supporting Information table 2**), indicating that AM supplementation in SOD1-Tg mice
257 may directly modify functional NAM biosynthesis.

258 To causally link increased systemic NAM levels to the associated phenotypic effects noted upon AM
259 supplementation, we continuously supplemented SOD1-Tg mice with NAM, administered subcutaneously
260 through implanted mini-osmotic pumps. Indeed, NAM levels were significantly increased in the CSF (**Fig**
261 **4e**) and sera (**Extended Data Fig. 10a**) of NAM-treated SOD1-Tg mice compared to water-treated controls.
262 Importantly, NAM-treated SOD1-Tg mice performed significantly better than vehicle-treated SOD1-Tg
263 mice, in both behavioral and neurological motor tests, as indicated by a pooled analysis (N=30 mice per
264 group, **Fig. 4f-h**) or independently in three repeats (N=10 mice in each group of each repeat, **Supporting**
265 **Information Fig. 8a-i**). Of note, NAM treatment resulted in a non-significantly trend to improve survival
266 (**Extended Data Fig. 10b**), possibly reflecting insufficient dosing or exposure time, or the necessity for
267 integration of other AM-mediated modulatory mechanisms (**Fig. 3g**) in reaching the observed AM-induced
268 survival benefit. We further inoculated Abx-pretreated SOD1-Tg mice with either WT *E. coli* as control or
269 with the Δ nadA *E. coli* compromised in NAM production (**Extended Data Fig. 10c**). Of note, *E. coli* is
270 considered a poor colonizer of the mouse GI tract²². While Δ nadA *E. coli* supplementation did not affect

271 rotarod and grip test performances (**Extended Data Figure 10d-e** and **Supporting Information Fig. 9**), it
272 significantly exacerbated the neurological scores of SOD1-Tg mice compared to the WT *E. coli*-treated
273 animals (**Extended Data Fig. 10f** and **Supporting Information Fig. 9**), suggesting that NAM secreted from
274 gut bacteria, even with poor colonization capacity, is able to impact some motor abilities in this ALS model.
275

276 **Potential AM and NAM mechanisms of ALS modulation**

277 To explore potential downstream mechanisms by which AM and NAM may support motor neuron survival
278 and ameliorate ALS progression in SOD1-Tg mice, we conducted bulk RNA-sequencing (RNA-seq) of spinal
279 cord samples collected from AM- and NAM-treated mice. Overall, false discovery rate (FDR)-corrected
280 expression of 213 genes significantly changed following NAM treatment of SOD1-Tg mice (**Extended Data**
281 **Fig. 11a**). 31 of these genes also significantly correlated in their expression pattern following AM
282 treatment (**Extended Data Fig. 11b**). Annotating the NAM-responsive genes to phenotype ontology
283 resulted in a significant 21% fit to 4 categories related to abnormal brain morphology, physiology and
284 movement (**Extended Data Fig. 11c**). The most significantly enriched GO (Gene Ontology) pathways
285 between AM and NAM interventions (**Extended Data Fig. 11d-e**) were related to mitochondrial structure
286 and function, Nicotinamide adenine dinucleotide⁺ (NAD⁺) homeostasis and removal of superoxide
287 radicals, canonical functions known to be disrupted in ALS. Interestingly, 28.6% of the shared genes
288 between AM and NAM treatments were found to be regulated by the transcription factor Nuclear
289 Respiratory Factor-1 (NRF-1, **Extended Data Fig. 12a**), known to control mitochondrial biogenesis,
290 electron transport chain activity and oxidative stress²³⁻²⁷. Potential NRF-1 contribution to this modulatory
291 effect merits further studies. Notably, NAM and AM treatments did not alter spinal cord *Slc1a2* expression
292 levels (**Extended Data Fig. 12c-e**) encoding to the excitatory amino acid transporter 2 (EAAT2) in
293 astrocytes, suggesting that the effect may not stem from NAM-associated glutamate excitotoxicity.
294

295 **Dysbiosis & impaired NAM levels in human ALS patients**

296 Finally, we examined preliminary links between the SOD1-Tg findings at our vivarium and features of
297 human ALS. To this aim, we performed a small-scale human observational study, by collecting stool
298 samples from 37 ALS patients and 29 healthy BMI- and aged-matched family members as controls and
299 sequencing their gut microbiome metagenomes. The microbiome composition of ALS patients, as
300 quantified by shotgun metagenomic sequencing, was significantly different to that of healthy control
301 household members (**Fig. 5a**, for PC1: $p = 1.3 \times 10^{-5}$). We observed only marginally significant difference in
302 specific bacterial species abundances after FDR correction (**Extended Data Fig. 13a**), with five bacterial
303 species reaching nearly-significant for ALS microbiome ($q < 0.1$), out of which one featured significant
304 correlation with serum NAM levels (**Supporting Information table 3** and **Extended Data Fig. 13b**).
305 Functionally, ALS microbiomes showed a significant difference in the global bacterial gene content (**Fig.**
306 **5b**, for PC1: $p = 2.55 \times 10^{-10}$), accompanied by FDR-corrected (adjusted for these pathways) decrease in
307 several key genes participating in tryptophan and in NAM metabolism (**Extended Data Fig. 13c** and
308 **Supporting Information table 4**). Interestingly, several of these significantly reduced genes were mapped
309 to the *A. muciniphila* genome, suggesting potential AM involvement that merits larger future studies.
310 Untargeted metabolomic profiling of ALS patient sera revealed multiple significantly-changed
311 metabolites, including elevated riluzole (an ALS exogenously-administrated treatment), creatine and 3-
312 hydroxy-2-ethylpropionate and reduced methyl indole 3-acetate and triethanolamine (**Extended Data**
313 **Fig. 13d**). Interestingly, key molecules of the tryptophan-nicotinamide metabolic pathway were

314 significantly altered in the sera of ALS patients, among them Indoleacetate, Kynurenine, Serotonin and
315 circulating Nicotinamide (**Extended Data Fig. 13e**), suggesting an aberrant NAM metabolism in some of
316 these human ALS cases. Targeted serum metabolomics further validated the marked NAM decrease in
317 the sera of 60 ALS patients compared with 33 healthy controls. (**Fig. 5c**). Moreover, serum NAM levels
318 from ALS patients mildly but significantly correlated both with human ALS Functional Rating Scale (FRS)
319 scores (**Extended Data Fig. 13f**) and with the levels of the microbiome gene encoding for one of the rate-
320 limiting NAM biosynthetic reactions (**Extended Data Fig. 13g**). We further found the levels of NAM in the
321 CSF of 14 ALS patients to be significantly lower than those of 17 healthy household controls, driven by
322 some patients featuring markedly low NAM CSF levels (**Fig. 5d**). The clinical implications of the above
323 preliminary metabolomic findings and associations, and whether they apply to all or to subsets of ALS
324 patients, merit further validation and exploration by human-focused prospective studies.

325

326 Discussion

327 Our findings highlight the potential cooperative activity of genetic risk and locally-varying environmental
328 modulatory factors in impacting ALS, with the gut microbiome serving as a ‘hub’ relaying these
329 environmental signals to the host, as was noted in other multifactorial disease such as IBD²⁹. Of note, our
330 study mainly focuses on one ALS animal model, in the context of one vivarium, and mechanistically
331 exemplifies one or multiple differentially-expressed metabolites in ALS (NAM). Future studies may
332 decipher complementary ALS-relevant CNS functions of other gut-derived commensals and metabolites
333 identified by us and by others. Importantly, our human data is preliminary and observational, and is not
334 aimed or sufficient to constitute a treatment recommendation of any sort in this devastating disease.
335 Larger future prospective human ALS studies, including ones incorporating genetic disease variants, are
336 needed to validate the suggested microbiome associations, in assessing causal impacts of potential
337 microbiome modulators of human ALS. These limitations notwithstanding, our study suggests a potential
338 modulatory involvement of the gut microbiome in ALS, that may help delineate some aspects of its elusive
339 pathophysiology, while providing an opportunity to identify modifiable environmental and microbial
340 therapeutic targets.

341

342 Data availability

343 The sequencing data has been deposited at the European Nucleotide Archive database with the accession
344 number PRJEB32767.

345

346 References

- 347 1. Turner, M. R. *et al.* Controversies and priorities in amyotrophic lateral sclerosis. *The Lancet*
348 *Neurology* **12**, 310–322 (2013).
- 349 2. Bensimon, G., Lacomblez, L. & Meininger, V. A Controlled Trial of Riluzole in Amyotrophic Lateral
350 Sclerosis. *N. Engl. J. Med.* **330**, 585–591 (1994).
- 351 3. Group, T. W. G. on behalf of the E. (MCI-186) A. 19 S. Safety and efficacy of edaravone in well
352 defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-
353 controlled trial. *Lancet Neurol.* **16**, 505–512 (2017).
- 354 4. Kundu, P., Blacher, E., Elinav, E. & Pettersson, S. Our Gut Microbiome: The Evolving Inner Self.
355 *Cell* (2017). doi:10.1016/j.cell.2017.11.024
- 356 5. Al-Chalabi, A. & Hardiman, O. The epidemiology of ALS: A conspiracy of genes, environment and
357 time. *Nature Reviews Neurology* **9**, 617–628 (2013).
- 358 6. Sampson, T. R. *et al.* Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model
359 of Parkinson’s Disease. *Cell* (2016). doi:10.1016/j.cell.2016.11.018

- 360 7. Sharon, G. *et al.* Human Gut Microbiota from Autism Spectrum Disorder Promote Behavioral
361 Symptoms in Mice. *Cell* **177**, 1600-1618.e17 (2019).
- 362 8. Rowin, J., Xia, Y., Jung, B. & Sun, J. Gut inflammation and dysbiosis in human motor neuron
363 disease. *Physiol. Rep.* **5**, 1–6 (2017).
- 364 9. Fang, X. Potential role of gut microbiota and tissue barriers in Parkinson’s disease and
365 amyotrophic lateral sclerosis. *Int. J. Neurosci.* **126**, 771–776 (2016).
- 366 10. Alonso, R. *et al.* Evidence for fungal infection in cerebrospinal fluid and brain tissue from patients
367 with amyotrophic lateral sclerosis. *Int. J. Biol. Sci.* **11**, 546–558 (2015).
- 368 11. Zhang, Y. guo *et al.* Target Intestinal Microbiota to Alleviate Disease Progression in Amyotrophic
369 Lateral Sclerosis. *Clin. Ther.* **39**, 322–336 (2017).
- 370 12. Fang, X. *et al.* Evaluation of the microbial diversity in amyotrophic lateral sclerosis using high-
371 throughput sequencing. *Front. Microbiol.* **7**, 1474 (2016).
- 372 13. Brenner, D. *et al.* The fecal microbiome of ALS patients. *Neurobiol. Aging* **61**, 132–137 (2018).
- 373 14. Ralph, G. S. *et al.* Silencing mutant SOD1 using RNAi protects against neurodegeneration and
374 extends survival in an ALS model. *Nat. Med.* **11**, 429–433 (2005).
- 375 15. Aartsma-Rus, A. & van Putten, M. Assessing functional performance in the mdx mouse model. *J.*
376 *Vis. Exp.* **27**, 51303 (2014).
- 377 16. Sugiyama, K. & Tanaka, K. Spinal cord-specific deletion of the glutamate transporter GLT1 causes
378 motor neuron death in mice. *Biochem. Biophys. Res. Commun.* **497**, 689–693 (2018).
- 379 17. Niessen, H. G. *et al.* In vivo quantification of spinal and bulbar motor neuron degeneration in the
380 G93A-SOD1 transgenic mouse model of ALS by T2 relaxation time and apparent diffusion
381 coefficient. *Exp. Neurol.* **201**, 293–300 (2006).
- 382 18. Zang, D. W. *et al.* Magnetic resonance imaging reveals neuronal degeneration in the brainstem
383 of the superoxide dismutase 1 transgenic mouse model of amyotrophic lateral sclerosis. *Eur. J.*
384 *Neurosci.* **20**, 1745–51 (2004).
- 385 19. Hsiao, E. Y. *et al.* Microbiota modulate behavioral and physiological abnormalities associated with
386 neurodevelopmental disorders. *Cell* **155**, 1451–1463 (2013).
- 387 20. Sampson, T. R. *et al.* Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model
388 of Parkinson’s Disease. *Cell* **167**, 1469-1480.e12 (2016).
- 389 21. Verdin, E. NAD⁺in aging, metabolism, and neurodegeneration. *Science* **350**, 1208–1213 (2015).
- 390 22. Sweeney, N. J., Laux, D. C. & Cohen, P. S. Escherichia coli F-18 and E. coli K-12 eda mutants do not
391 colonize the streptomycin-treated mouse large intestine. *Infect. Immun.* (1996).
- 392 23. Golko-Perez, S., Amit, T., Bar-Am, O., Youdim, M. B. H. & Weinreb, O. A Novel Iron Chelator-
393 Radical Scavenger Ameliorates Motor Dysfunction and Improves Life Span and Mitochondrial
394 Biogenesis in SOD1G93AALS Mice. *Neurotox. Res.* **31**, 230–244 (2017).
- 395 24. Scarpulla, R. C., Vega, R. B. & Kelly, D. P. Transcriptional integration of mitochondrial biogenesis.
396 *Trends in Endocrinology and Metabolism* **23**, 459–466 (2012).
- 397 25. Bergeron, R. *et al.* Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial
398 biogenesis. *Am. J. Physiol. Endocrinol. Metab.* **281**, 1340–1346 (2001).
- 399 26. Evans, M. J. & Scarpulla, R. C. NRF-1: A trans-activator of nuclear-encoded respiratory genes in
400 animal cells. *Genes Dev.* **4**, 1023–1034 (1990).
- 401 27. Virbasius, C. M. A., Virbasius, J. V. & Scarpulla, R. C. NRF-1, an activator involved in nuclear-
402 mitochondrial interactions, utilizes a new DNA-binding domain conserved in a family of
403 developmental regulators. *Genes Dev.* **7**, 2431–2445 (1993).
- 404 28. Reimand, J., Kull, M., Peterson, H., Hansen, J. & Vilo, J. G:Profiler-a web-based toolset for
405 functional profiling of gene lists from large-scale experiments. *Nucleic Acids Res.* (2007).
406 doi:10.1093/nar/gkm226
407

408 **References referring to the methods section are depicted in the Supplementary information**

409 **Acknowledgements**

411 We thank the members of the Elinav and Segal laboratories, and members of the DKFZ cancer-microbiome
412 division for discussions, and apologize to authors whose work was not included due to space constraints.
413 We thank Ravid Straussman, Deborah Nejman and Eran Hornstein, Weizmann Institute of Science, for

414 suggestions and help with experimental methodologies. We thank Carmit Bar-Nathan for dedicated
415 assistance with animal work. We thank Prof. Shimshon Belkin, Hebrew University of Jerusalem, for
416 providing reagents and Anastasia Godneva for computational assistance. E.B. is supported by the
417 Weizmann Institute Dean of Faculty fellowship. D.R. received a Levi Eshkol PhD Scholarship for
418 Personalized Medicine by the Israeli Ministry of Science. N.Z. is supported by the Gilead Sciences
419 International Research Scholars Program in Liver Disease. C.K. is supported by an MD fellowship of the
420 Boehringer Ingelheim Fonds. Y.K. is the incumbent of the Sarah and Rolando Uziel Research Associate
421 Chair. E.S. is supported by the Crown Human Genome Center; the Else Kroener Fresenius Foundation;
422 Donald L. Schwarz, Sherman Oaks, CA; Jack N. Halpern, NeNY; Leesa Steinberg, Canada; and grants funded
423 by the European Research Council and the Israel Science Foundation. E.E. is supported by: Y. and R. Ungar;
424 the Abisch Frenkel Foundation for the Promotion of Life Sciences; the Gurwin Family Fund for Scientific
425 Research; the Leona M. and Harry B. Helmsley Charitable Trust; the Crown Endowment Fund for
426 Immunological Research; the Else Kroener Fresenius Foundation; the estate of J. Gitlitz; the estate of L.
427 Hershkovich; the Benozio Endowment Fund for the Advancement of Science; the Adelis Foundation; J. L.
428 and V. Schwartz; A. and G. Markovitz; A. and C. Adelson; the French National Center for Scientific Research
429 (CNRS); D. L. Schwarz; The V. R. Schwartz Research Fellow Chair; L. Steinberg; J. N. Halpern; A. Edelheit,
430 and by grants funded by the European Research Council; the Israel Science Foundation; the Helmholtz
431 Foundation E.E. is the Sir Marc & Lady Tania Feldmann Professorial Chair in Immunology,
432 Weizmann Institute of Science, Israel, Director, Microbiome Research Division, DKFZ, Heidelberg,
433 Germany, is a senior fellow, Canadian Institute of Advanced Research (CIFAR) and an international scholar,
434 The Bill & Melinda Gates Foundation and Howard Hughes Medical Institute (HHMI).

435

436 **Author contributions**

437 E.B., S.B., and H.S. designed, performed and interpreted the experiments, and wrote the manuscript; S.B.,
438 D.R. performed and analyzed all the microbiome sequencing and analysis; E.B., S.B., H.S., and D.R. equally
439 contributed to the study. U.M., Y.C., N.B., and I.L. assisted in computational analysis. M.D.B, C.K., C.M.,
440 Y.H., D.K., N.Z., N.A, I.B., Y.K., M.T. and L.Al. performed and supervised key animal experiments. T.M. &
441 A.B. performed the metabolomics experiments. M.Zu., M.Za., R.B-Z performed and supervised the human
442 experimentation. A.H. oversaw animal experimentation including in germ-free mice. M.S. and A.I.
443 provided key help and insights on the project. L.Ar. performed proteomic studies, M.E.V.J. performed the
444 colon immunohistology staining and G.C.H. supervised these studies. M.G., E.S. and E.E. conceived the
445 study, supervised the participants, interpreted the experiments, and wrote the manuscript.

446

447 **Competing interests**

448 E.S. and E.E. are paid consultants at DayTwo and BiomX. None of this work is related to, shared with or
449 licensed to these or any other commercial entity. None of the other authors have competing interests
450 related to this work.

451

452 **Figure legends**

453 **Figure 1. Antibiotic treatment exacerbates motor symptoms in an ALS mouse model.**

454 Evaluation of motor symptoms by **(a)** rotarod, **(b)** hanging-wire grip tests and **(c)** neurological scoring.
455 *P=0.0256, ***P=0.0007 and 0.0005, two-sided Mann-Whitney U test. The experiment was repeated 3
456 times, (N=20 SOD1-Tg water, 18 SOD1-Tg Abx, 14 WT water and 15 WT Abx mice). Error bars represent

457 mean \pm S.E.M. **(e)** Survival of GF (N=14) and SPF (N=17) SOD1-Tg mice. **P<0.0027, two-sided Log-rank
458 test. The experiment was repeated twice.

459
460 **Figure 2. SOD1-Tg mice develop early gut microbiome compositional and functional changes.** Weighted
461 UniFrac PCoA on **(a)** day 40 (pre-symptomatic), **(b)** day 100 (disease onset) and **(c)** day 140 (advanced
462 disease). The experiment was repeated 3 times, (N=6 mice in each group). **(d)** Species-level taxa summary
463 obtained by gut microbiome metagenomic shotgun sequencing of WT and SOD1-Tg stool samples during
464 disease progression. **(e)** PCA of KEGG entries of WT and SOD1-Tg microbiome. $p=1.57 \times 10^{-14}$, Spearman
465 correlation coefficient. N=6 WT mice for days 40, 60, 100 and SOD1-Tg mice for days 40 and 80, and N=5
466 WT mice for day 80 and SOD1-Tg mice for days 60 and 100.

467
468 **Figure 3. Akkermansia muciniphila colonization ameliorates motor degeneration and increases life-span**
469 **in SOD1-Tg mice.** **(a)** Linear regression of AM relative abundance (16S rDNA sequencing) of SOD1-Tg and
470 WT stool over time (Spearman correlation coefficient). **(b)** qPCR of AM 16S gene copies in fecal DNA
471 extract N=5 WT and 6 SOD1-Tg mice, two-sided Mann-Whitney U test **P=0.0043. Error bars represent
472 mean \pm S.E.M. **(c)** Rotarod, **(d)** hanging-wire grip test and **(e)** neurological scoring. N=62 SOD1-Tg PBS, 61
473 SOD1-Tg AM, 37 WT PBS and 36 WT AM mice. two-sided Mann-Whitney U test. ***P=0.0002,
474 ****P<0.0001. Error bars represent mean \pm S.E.M. The experiment was repeated 6 times (N=5-26 mice).
475 **(f)** Survival of PBS- (N=8), AM- (N=9), *Prevotella melaninogenica* (PM, N=4)- and *Lactobacillus gasseri* (LG,
476 N=5)-treated mice ***P<0.0003, two-sided Log-rank test.

477
478 **Figure 4. Akkermansia muciniphila treatment is associated with enhanced nicotinamide biosynthesis in**
479 **SOD1-Tg mice.** **(a)** Significantly increased serum metabolites in SOD1-Tg mice treated with AM (upper-
480 right quadrant N=7 mice). Two-sided FDR corrected Mann Whitney U ranksum test. **(b)** Serum levels
481 nicotinamide pathway metabolites in SOD1-Tg and WT mice treated with AM or PBS. **(c)** Nicotinamide
482 levels in bacterial cultures. N=5 cultures in each group, **P<0.005, ***P<0.0005, two-sided Mann-
483 Whitney U test. Error bars represent mean \pm S.E.M. **(d)** CSF nicotinamide levels of SOD1-Tg and WT mice
484 treated with AM or PBS on day 100. **P=0.0041, two-sided Mann-Whitney U test. Error bars represent
485 mean \pm S.E.M. **(e)** CSF NAM levels in NAM and vehicle treated SOD1-Tg mice (N=10 mice) *P=0.0232, two-
486 sided Mann-Whitney U test. Error bars represent mean \pm S.E.M. Motor performances of NAM or vehicle
487 treated SOD1-Tg mice using subcutaneous osmotic pumps indicated by **(f)** rotarod, **(g)** hanging-wire grip
488 test and **(h)** neurological scoring. ****P<0.0001 two-sided Mann-Whitney U test. Error bars represent
489 mean \pm S.E.M. The experiment was repeated 3 times, (N=30 mice in each group).

490
491 **Figure 5. Microbiome-derived nicotinamide metabolism is impaired in ALS patients** **(a)** PCA of bacterial
492 species composition (for PC1 $p=1.3 \times 10^{-5}$, Spearman correlation coefficient) or **(b)** KEGG orthology (KO)
493 annotated bacterial genes (for PC1 $p=2.55 \times 10^{-10}$, Spearman correlation coefficient) obtained by stool
494 metagenomic sequencing from ALS patients (N=37) and healthy controls (family members, N=29). **(c)**
495 Serum and **(d)** CSF NAM levels of ALS patients (N=60 for serum and 14 for CSF) and healthy controls (N=33
496 for serum and 17 for CSF), ****P<0.0001, ***P=0.0001, Mann Whitney U test. Error bars represent mean
497 \pm S.E.M.

498

499 **Extended Data Figure 1. The effects of microbiome depletion on ALS symptoms in SOD1-Tg mice. (a)** (a)
500 Experimental design. Linear regression of motor functions over time in SOD1-Tg and WT treated indicated
501 by (b) rotarod, (c) hanging-wire grip test, and (d) neurological score. N=20 SOD1-Tg water and Abx, 14 WT
502 water and 15 WT Abx mice. (e) Histological images and (f) quantification of spinal cord motor neurons of
503 140-day old water- and Abx-treated SOD1-Tg mice. (N=10 SOD1-Tg water, 5 SOD1-Tg Abx), *P=0.028, two-
504 sided Mann-Whitney U test. The experiment was repeated twice. Error bars represent mean \pm S.E.M. (g)
505 MRI of murine ALS brain areas and their corresponding (f) T2 maps. The experiment was repeated twice.
506 (h-o) quantification of T₂ relaxation time between water and Abx-treated SOD1-Tg mice throughout ALS.
507 N=9 mice in each group. *P<0.05, **P<0.005, ****P<0.00005, two-sided Mann-Whitney U test. Error bars
508 represent mean \pm S.E.M. (p) Home cage locomotion analysis over a period of 46 h, days 100–101 (N=5
509 mice). *P=0.03, two-sided Mann-Whitney U test.

510
511 **Extended Data Figure 2. Microbial compositional dynamics in the SOD1-Tg mouse model across ALS**
512 **progression. (a)** Taxa summary of bacterial phyla and (b) genera of WT and SOD1-Tg mice obtained by
513 16S rDNA sequencing of stool samples. (c) Relative abundances of significant differentially representative
514 genera between SOD1-Tg and WT mice. N=6 mice in each group, two-sided FDR-corrected Mann-Whitney
515 U test. (d-m) FDR-corrected linear regression comparison of representative bacterial relative abundance
516 change during ALS progression between WT and SOD1-Tg stool. Spearman correlation coefficient. N=6
517 SOD1-Tg and 4 WT mice. (n) Alpha diversity of SOD1-Tg and WT microbiomes. N=7 SOD1-Tg and 5 WT
518 mice, *P<0.05, **P<0.005, ***P<0.0005, two-sided FDR-corrected Mann-Whitney U test. Error bars
519 represent mean \pm S.E.M. The experiment was repeated 3 times. (o) qPCR-based quantification of total 16S
520 copy-number in 1 ng of DNA extracted from stool samples of SOD1-Tg and WT mice. N=6 mice, two-sided
521 Mann-Whitney U test. Error bars represent mean \pm S.E.M.

522
523 **Extended Data Figure 3. Microbial spontaneous colonization in Ex-GF SOD1-Tg mouse model across ALS**
524 **progression. (a)** Taxa summary of bacterial genera in individual Ex-GF WT and SOD1-Tg undergoing
525 spontaneous bacterial colonization during ALS course. (b-e) Weighted UniFrac PCoA of Ex-GF WT and
526 SOD1-Tg mice on days 4, 5, 53 and 63 following spontaneous colonization. N=6 mice in each group, two-
527 sided FDR-corrected Mann-Whitney U test (f-i) FDR corrected volcano plots of significantly enriched
528 bacterial genera of Ex-GF WT and SOD1-Tg during ALS course on days 4, 5, 53 and 63 following
529 spontaneous colonization. N=6 mice in each group. two-sided FDR-corrected Mann-Whitney U test.

530
531 **Extended Data Figure 4. Metagenomic differences between WT and SOD1-Tg fecal microbiomes (a)**
532 PCoA plot of bacterial composition (N=23 SOD1-Tg and 24 WT mice), and (b) Taxa summary
533 representation at the species level of gut microbiome of WT and SOD1-Tg mice obtained by metagenomic
534 shotgun sequencing. The experiment was repeated twice (N=6 mice). (c-n) FDR-corrected linear
535 regression comparison of representative bacterial relative abundance change during ALS progression
536 between WT and SOD1-Tg stool. N=6 mice in each group, Spearman correlation coefficient. (p) Schematic
537 representation and (q) heatmap of bacterial gene abundances of tryptophan metabolism. N=6 mice, two-
538 sided FDR-corrected Mann-Whitney U test. *P<0.05, **P<0.005, ***P<0.0005. (r) Heatmap of bacterial
539 gene abundances of the nicotinamide and nicotinate biosynthesis pathway. N=6 mice, *P<0.05,
540 **P<0.005, ***P<0.0005, two-sided Mann-Whitney U test. FDR was used for multiple comparisons.

541

542 **Extended Data Figure 5. Mono-colonization of Abx pre-treated SOD1-Tg mice with selected ALS-**
543 **correlating microbiome strains.** Motor functions of Abx pre-treated SOD1-Tg mice treated with PBS (N=7),
544 *Eggerthella lenta* (EL, N=7), *Coprobacillus cateniformis* (CC, N=6), *Parabacteroides goldsteinii* (PG, N=6),
545 *Lactobacillus murinus* (LM, N=8), *Parabacteroides distasonis* (PD, N=5), *Lactobacillus gasseri* (LG, N=8),
546 *Prevotella melaninogenica* (PM, N=4), or *Akkermansia muciniphila* (AM, ATCC 835, N=6) indicated by **(a)**
547 rotarod, **(b)** hanging-wire grip test and **(c)** neurological scoring. **(d-f)** Motor functions of Abx pre-treated
548 SOD1-Tg mice treated with PBS or *Eisenbergiella tayi* (ET, N=6), or **(g-i)** *Subdoligranulum variabile* (SV,
549 N=7). **(j-l)** Motor functions of Abx pre-treated WT littermate controls treated with PBS, LM, PD, LG, PM or
550 AM. *P<0.05, **P<0.005, ***P<0.0005, two-sided Mann-Whitney U test. Error bars represent mean ±
551 S.E.M.

552
553 **Extended Data Figure 6. The effects of *Ruminococcus torques* mono-colonization on ALS progression in**
554 **SOD1-Tg mice.** **(a)** Linear regression of *Ruminococcus torques* (RT) relative abundance (16S rDNA
555 sequencing) of SOD1-Tg and WT stool N=6 mice, Spearman coefficient. **(b)** Rotarod, **(c)** hanging-wire grip
556 test and **(d)** neurological scoring of Abx-pretreated WT and SOD1-Tg treated with PBS or RT. N=18 SOD1-
557 Tg PBS, 20 SOD1-Tg RT and 23 WT PBS and RT mice. *P=0.0205, **P=0.0029, two-sided Mann-Whitney U
558 test. Error bars represent mean ± S.E.M. **(e)** Histological images and **(f)** quantification of spinal cord motor
559 neurons of 140 days old PBS- (N=5) and RT-treated SOD1-Tg (N=3) mice. Error bars represent mean ±
560 S.E.M. The experiment was repeated 3 times. **(g)** Brain areas and their corresponding **(h-m)** T₂ relaxation
561 time quantification between PBS and RT-treated SOD1-Tg mice throughout the disease. *P<0.05,
562 **P<0.005, ***P<0.0005, ****P<0.00005, two-sided Mann-Whitney U test. The experiment was repeated
563 twice, N=5 mice in each group. Error bars represent mean ± S.E.M.

564
565 **Extended Data Figure 7. The effects of *Akkermansia muciniphila* treatment on ALS manifestation and**
566 **microbiome composition in SOD1-Tg mice.** **(a)** Histological images and **(b)** spinal cord motor neuron
567 quantification in 140-day old PBS- and AM-treated SOD1-Tg mice. N=7 mice in each group *P<0.0111,
568 **P<0.0041, two-sided Mann-Whitney U test. The experiment was repeated twice. Error bars represent
569 mean ± S.E.M. **(c-f)** T₂ relaxation time in PBS and AM (ATCC 835)-treated Abx-pretreated SOD1-Tg mice at
570 days 100 and 140. N=5 mice in each group, ***P<0.0005, ****P<0.00001, two-sided Mann-Whitney U
571 test. Error bars represent mean ± S.E.M. **(g)** Systemic FITC-dextran measurement at 120 days WT and
572 SOD1-Tg treated with PBS (N=3 and 7), AM (N=3 and 9), *P. Melaninogenica* (PM, N=5 and 4) or *L. gaseri*
573 (LG, N=5). Two-sided Mann-Whitney U test. Error bars represent mean ± S.E.M. **(h)** PCoA of bacterial
574 species compositions in SOD1-Tg mice treated with PBS (N=33) or AM (N=31). AM relative abundance in
575 **(i)** SOD1-Tg or **(j)** WT mice treated with PBS or AM. N=8 mice, *P<0.05, ***P<0.0005, ****P<0.00005,
576 two-sided Mann-Whitney ranksum test. Error bars represent mean ± S.E.M. **(k)** Individual and **(l)** averaged
577 qPCR-based fold-change of *Akkermansia muciniphila* 16S copy number in mucosal and luminal samples
578 across the GI tract of 140 days old AM or PBS treated WT and SOD1-Tg mice, N=5 mice in each group. **(m)**
579 Genera bacterial summary of SOD1-Tg or **(n)** WT mice treated with PBS or AM. Abx-pretreated SOD1-Tg
580 and WT littermate control mice were treated orally with AM (ATCC 2869) or PBS as vehicle from age 60
581 days until the experimental end-point. On days 60, 80, 100, 120 and 140 motor performance of the mice
582 was assessed by **(o)** rotarod, **(p)** hanging-wire grip test and **(q)** neurological scoring. (N=6 SOD1-Tg PBS,
583 AM 2869 and WT AM 2869 and 7 WT PBS mice), **P=0.0022, two-sided Mann-Whitney U test. Error bars
584 represent mean ± S.E.M.

585

586 **Extended Data Figure 8. *Akkermansia muciniphila* treatment alters mucus properties of SOD1-Tg mice.**
587 Immunohistochemical assessment of distal colon mucosa of 140 days old (a) PBS- and (b) AM- (BAA-835)
588 Abx-pretreated WT and SOD1-Tg mice. DNA stained with Sytox-green (green) and the mucus with an anti-
589 MUC2C3 antiserum and goat anti-Ig (red). The non-stained areas between the epithelium and outer
590 mucus/luminal bacteria is the inner mucus layer, allows bacteria identification. The experiment was
591 performed once. Heatmap representation of (c) total mucus proteomic landscape and (d) AM-related
592 peptides and (e-j) quantification of key representative mucus components. N=4 SOD1-Tg PBS and 8 SOD1-
593 Tg AM mice, two-sided Mann-Whitney U test. P=N.S. Error bars represent mean \pm S.E.M.

594

595 **Extended Data Figure 9. Serum metabolomic profile is affected by antibiotics or AM treatment in ALS**
596 **SOD1-Tg mice.** Heatmap representation of serum metabolites of 100 days old (a) naïve SOD1-Tg and their
597 WT littermates, (b) water or Abx-treated SOD1-Tg mice, (c) PBS or AM-treated SOD1-Tg mice. (d) Scoring
598 of top six serum metabolites which significantly altered by Abx treatment in SOD1-Tg mice by their
599 potential to originate of the gut microbiome. N=8 mice in each group. Motor performances of Phenol
600 sulfate (N=8) or water treated (N=7) SOD1-Tg mice using subcutaneous osmotic pumps indicated by (e)
601 rotarod, (f) hanging-wire grip test and (g) neurological scoring. Two-sided Mann-Whitney U test. P=N.S.
602 Error bars represent mean \pm S.E.M. Non-targeted metabolomics assessment of tryptophan metabolism of
603 (h) water and Abx- treated or (i) PBS and AM-treated 100 days old SOD1-Tg mice. N=7 mice in each group.
604 (j) CSF nicotinamide levels of SOD1-Tg and WT mice treated with AM or PBS on day 140. *P=0.0.205, two-
605 sided Mann-Whitney U test. Error bars represent mean \pm S.E.M. (k) Schematic representation of the
606 microbiome-derived nicotinamide producing genes in AM treated SOD1-Tg fecal samples.

607

608 **Extended Data Figure 10. Nicotinamide ameliorates ALS progression in SOD1-Tg mice.** (a) sera NAM
609 levels in NAM and vehicle treated SOD1-Tg mice (N=10 mice) *P=0.0433, two-sided Mann-Whitney U
610 test. Error bars represent mean \pm S.E.M. (b) Survival assessment of NAM and vehicle treated SOD1-Tg
611 mice p=0.1757. N=10 mice in each group, two-sided Log-rank test. (c) Nicotinamide levels in WT or
612 Δ nadA *E. coli* cultures (N=5). **P=0.0079, two-sided Mann-Whitney U test. Error bars represent mean \pm
613 S.E.M. Motor performances of WT or Δ nadA *E. coli*-inoculated Abx-pretreated SOD1-Tg mice indicated
614 by (d) rotarod, (e) hanging-wire grip test and their (f) neurological scores. N=18 WT-*E. coli* and 16 Δ nadA
615 *E. coli* SOD1-Tg mice. ***P=0.0007, two-sided Mann-Whitney U test. Error bars represent mean \pm S.E.M.

616

617 **Extended Data Figure 11. Uncovering potential downstream motor neuron modulatory mechanisms**
618 **of AM and NAM treatments.** (a) Heatmap of FDR-corrected differentially-expressed genes in the spinal
619 cords of NAM-treated SOD1-Tg mice (N=10 mice), two-sided FDR corrected Mann Whitney U ranksum
620 test. (b) Spearman correlation of spinal cord transcripts log2 fold change between AM- and NAM-treated
621 SOD1-Tg mice, P<0.0001, (N=10 mice) (c) Comparison of the significantly differentially-expressed genes
622 following NAM treatment with the KOG database classified into 4 neuropathological groups. FDR-
623 corrected gene set enrichment distribution of spinal cord transcripts of (d) NAM-treated and (e) AM-
624 treated SOD1-Tg mice into biological process, molecular functions and cellular components. (N=10
625 mice), two-sided FDR corrected Mann Whitney U ranksum test.

626

627 **Extended Data Figure 12. NAM differentially expressed genes associated with Nuclear respiratory**
628 **factor-1 (NRF-1).** (a) Representation of spinal cord transcripts obtained by RNA-seq analysis that changed
629 similarly after AM and NAM treatments of SOD1-Tg mice and share the GCGCMTGCGCN binding site for
630 the Nuclear Respiratory Factor-1 (NRF-1) transcription factor. The analysis was done using the G:Profiler
631 platform²⁸. (b) Spinal cord global transcriptomic analysis in NAM or water treated SOD1-Tg mice and (c)
632 individual representation of *Slc1a2*, (N=10). (d) Spinal cord global transcriptomic analysis in AM or PBS
633 treated SOD1-Tg mice and (e) individual representation of *Slc1a2*, (N=7). Two-sided FDR-corrected Mann-
634 Whitney ranksum test. Error bars represent mean \pm S.E.M.

635
636 **Extended Data Figure 13. Different gut microbiome composition in ALS patients.** (a) Taxa summary
637 representation at the species level of gut microbiome of healthy family members (N=29) and ALS patients
638 (N=37) obtained by metagenomic shotgun sequencing. Two-sided FDR-corrected Mann-Whitney ranksum
639 test. (b) Spearman correlation between *Bifidobacterium pseudocatenulatum* abundance obtained by
640 metagenomic shotgun sequencing and serum NAM levels of ALS patients (N=37 ALS patients and 29
641 healthy controls). (c) KO relative abundances of microbiome-associated genes of the nicotinamide
642 pathway in ALS (N=36) and healthy (N=28) stool samples. *q=0.03-0.04, two-sided FDR corrected Mann
643 Whitney U ranksum test. Error bars represent mean \pm S.E.M. (d) Top 97 differentially-represented serum
644 metabolites between healthy individuals (N=13) and ALS patients (N=23) obtained by untargeted
645 metabolomics. (e) Serum metabolites levels of tryptophan/nicotinamide pathways in ALS (N=24) patients
646 and healthy individuals (N=13) obtained by non-targeted metabolomics. *P<0.05, **P<0.005,
647 ***P<0.0005, two-sided FDR-corrected Mann-Whitney ranksum test. Error bars represent mean \pm S.E.M.
648 (f) Serum NAM correlation with clinical FRS scores and (g) bacterial L-aspartate oxidase copies in ALS
649 patients (N=60) and healthy controls (N=33), ***P=0.0001, Mann Whitney U test and Spearman
650 correlation coefficient.

651

652 **Methods**

653 **Mice**

654 Animal experiments were approved by the Weizmann Institute Animal Care and Use Committee Following
655 US National Institute of Health, European Commission and the Israeli guidelines. G93A mSOD1-Tg mice
656 on a C57BL/6 background were kindly provided by Eran Hornstein (Weizmann Institute). In all
657 experiments, age- and gender-matched mice were used and WT littermates were used as controls. Mice
658 were 40 days of age at the beginning of experiments. All mice were kept on a strict 24 hr reverse light-
659 dark cycle, with lights being turned on from 10pm to 10am. For antibiotic treatment, mice were given a
660 combination of vancomycin (0.5 g/l), ampicillin (1 g/l), neomycin (1 g/l), and metronidazole (1 g/l) in
661 drinking water from age 40 days as previously described²⁹. For the *Akkermansia muciniphila* or
662 *Ruminococcus torques* colonization, 40 days old mice were treated with antibiotics for two weeks,
663 followed by 2 days of washout period and gavaged with 200 μ l of PBS-suspended bacteria (O.D.=0.7)
664 weekly until the experimental end-point. Food intake and other metabolic parameters were measured
665 using the PhenoMaster system (TSE-Systems, Bad Homburg, Germany), which consists of a combination
666 of sensitive feeding sensors for automated measurement, and a photobeam-based activity monitoring
667 system, which detects oxygen and carbon dioxide consumption, and records ambulatory movements,
668 including rearing and climbing, in each cage. All parameters were measured continuously and

669 simultaneously. Mice were trained singly-housed in identical cages prior to data acquisition. All
670 experimental procedures were approved by the local IACUC 02660418-3.

671

672 **Administration of metabolites**

673 For the *in vivo* administration of NAM and Phenol sulfate, the Alzet osmotic minipumps model 1004
674 (Charles River) were used (infusing the compound at a rate of 0.11 μ L/hour for 4 weeks). The pumps were
675 filled with 100 μ L 50 mg/ml Nicotinamide (Cymit Quimica, Barcelona, Spain) or 33.33 mg/ml Phenol sulfate
676 sodium salt (TLC, Ontario, Canada) diluted in sterile water (equivalent to 49.28 mg/kg/week of NAM and
677 30.8 mg/kg/week Phenol sulfate). Vehicle control pumps contained equivalent volume of Ultra-pure
678 water. 6-week-old SOD1-Tg and WT litter-mate mice were anesthetized by i.p. injection of ketamine (100
679 mg/kg) and xylazine (10 mg/kg), the neck skin was shaved and sterilized with 70% ethanol, 1 cm incision
680 was made in the skin, the osmotic minipumps were inserted following minimal blunt dissection and placed
681 above the right hind flank. The cut was then closed with sterile surgical clips and the animals were carefully
682 monitored for any signs of stress, bleeding, pain, or abnormal behavior. By replacing the pumps every 28
683 days, for a total of 4 times between the ages of 40-152 days, we assured steady and continuous
684 metabolites administration to mice throughout the disease.

685

686 **Assessment of motor functions in mice**

687 *Rotarod*

688 To assess motor coordination and balance, each mouse was tested with a rotarod device (Panlab Le8500
689 Harvard Apparatus, Spain), in acceleration speed mode (increasing from 4 rpm to 40 rpm during 10 min),
690 with a maximum test time of 5 min. The mice were habituated on the horizontal rotating rod and pre-
691 trained for 3 trials before the formal tests. Each mouse was recorded three times at ages 60, 80, 100, 120
692 and 140 days. The apparatus automatically recorded the elapsed time when the mouse fell from the
693 spindle.

694 *Hanging wire grip test*

695 Mice were allowed to grip a 2 mm thick horizontal metal wire (suspended 80 cm above the working
696 surface) with their forepaws and the latency to successfully raise their hind legs to grip the wire was
697 recorded. The mice were observed for 30 sec and scored as follows: 0 = falls off within 10 sec.; 1 = hangs
698 onto bar by two forepaws; 2 = attempts to climb onto bar; 3 = hangs onto bar by two forepaws plus one
699 or both hind paws; 4 = hangs by all four paws plus tail wrapped around bar; 5 = active escape to the end
700 of bar.

701 *Neurological scoring*

702 Mice were neurologically scored by a system developed by ALS TDI³⁰: Score of 0: Full extension of hind
703 legs away from lateral midline when mouse is suspended by its tail, and mouse can hold this for two
704 seconds, suspended two to three times. Score of 1: Collapse or partial collapse of leg extension towards
705 lateral midline (weakness) or trembling of hind legs during tail suspension. Score of 2: Toes curl under at
706 least twice during walking of 12 inches, or any part of foot is dragging along cage bottom/table. Score of
707 3: Rigid paralysis or minimal joint movement, foot not being used for generating forward motion. Score
708 of 4: Mouse cannot right itself within 30 sec after being placed on either side.

709 *Home-cage locomotion*

710 The locomotion of animals was quantified over a period of 46 h in the home cage, by automated sensing
711 of body-heat image using an InfraMot (TSE-Systems). Individual animal movements were summed up
712 every 30 min.

713

714 **Survival**

715 From age 130 days, mice were monitored daily. The endpoint was defined by reaching neurological score
716 of 4 and/or more than 15% reduction in body weight. The probability of survival was calculated using the
717 Kaplan– Meier method, and statistical analysis was performed using a log-rank test.

718

719 **Cerebrospinal fluid (CSF) extraction**

720 Mice were anesthetized by i.p. injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). The skin of the
721 neck was shaved, and the mouse was placed prone on the stereotaxic instrument. The head was secured
722 with head adaptors. The surgical site was swabbed with 70% ethanol, and a sagittal incision of the skin
723 was made inferior to the occiput. Under the dissection microscope, the subcutaneous tissue and muscles
724 (m. biventer cervicis and m. rectus capitis dorsalis major) were separated by blunt dissection with forceps.
725 A pair of micro-retractors was used to hold the muscles apart. The dura mater was blotted dry with sterile
726 cotton swab. CSF was collected using a capillary tube to penetrate into the cisterna magna (through the
727 dura mater, lateral to the arteria dorsalis spinalis) and immediately frozen in liquid nitrogen and stored at
728 -80°C .

729

730 **Magnetic resonance imaging (MRI)**

731 During MRI scanning, mice were anesthetized with Isoflurane (5% for induction, 1–2% for maintenance)
732 mixed with oxygen (1 liter/min) and delivered through a nasal mask. Once anesthetized, the animals were
733 placed in a head-holder to assure reproducible positioning inside the magnet. Respiration rate was
734 monitored and kept throughout the experimental period around 60–80 breaths per minute. MRI
735 experiments were performed on 9.4 Tesla BioSpec Magnet 94/20 USR system (Bruker, Germany)
736 equipped with gradient coil system capable of producing pulse gradient of up to 40 gauss/cm in each of
737 the three directions. All MR images were acquired with a receive quadrature mouse head surface coil and
738 transmitter linear coil (Bruker). The T_2 maps were acquired using the multi-slice spin-echo (MSME)
739 imaging sequence with the following parameters: a repetition delay (TR) of 3000 ms, 16-time echo (TE)
740 increments (linearly from 10 to 160ms), matrix dimension of 256 x 128 (interpolated to 256 x 256) and
741 two averages, corresponding to an image acquisition time of 12 min 48 sec. The T_2 dataset consisted of
742 16 images per slice. Thirteen continuous slices with slice thickness of 1.00 mm were acquired with a field
743 of view (FOV) of 2.0 x 2.0 cm^2 .

744 *Image Analysis*

745 A quantitative T_2 map was produced from multi-echo T_2 -weighted images. The multi-echo signal was fitted
746 to a mono-exponential decay to extract the T_2 value for each image pixel. All image analysis was
747 performed using homemade scripts written in Matlab R2013B. Co-registration inter-subject and intra-
748 subject was applied before the MRI dataset analysis. For optimal suitability to a mouse brain atlas
749 (correction of head movements image artifacts), all images went through atlas registration: reslicing,
750 realignment and smoothing, using the SPM software (version 12, UCL, London, UK). The results were
751 reported as mean \pm SD. A t-test was used to compare means of two groups. A p value of less than 0.01
752 was considered statistically significant.

753

754 **Histology**

755 Sections from the spinal cord (C3-T6) were fixed in paraformaldehyde and embedded in paraffin for
756 staining with luxol fast-blue and cresyl echt violet. Subsequently, sections were examined by a blinded
757 researcher and cresyl echt violet positive motor neurons in the ventral horn were counted to evaluate
758 neuronal survival. Colon tissues were fixed in dry methanolic-Carnoy and stained with the nuclear stain
759 Sytox green and the Muc2 mucin with the anti-MUC2C3 antiserum and goat anti-rabbit-Alexa 555
760 (Thermo Fisher Scientific)³¹

761

762 **Measuring gut epithelial barrier permeability by FITC-dextran**

763 On the day of the assay, 4 kDa fluorescein isothiocyanate (FITC)-dextran was dissolved in PBS to a
764 concentration of 80 mg ml⁻¹. Mice were fasted for 4 hours prior to gavage with 150µl dextran. Mice were
765 anesthetized 3 hours following gavage and blood was collected and centrifuged at 1,000 x g for 12 min at
766 4°C. Serum was collected and fluorescence was quantified at an excitation wavelength of 485 nm and 535
767 nm emission wavelength.

768

769 **Flow cytometry**

770 WT and SOD1-Tg mice treated with Abx from 40 days of age or with water as controls were used for small-
771 intestinal, colonic and spinal cord cellularity analysis either on day 140 (for small intestines and colons) or
772 on days 60 and 140 (for spinal cords). Small intestinal and colonic samples were extensively washed from
773 fecal matter followed by 2 mM EDTA dissociation in 37°C for 30 min. Following extensive shaking, the
774 epithelial fraction was discarded. Samples were then digested using DNaseI and collagenase for lamina
775 propria analysis. Spinal cord samples were harvested from individual mice, homogenized and incubated
776 with a HBSS solution containing 2% BSA (Sigma-Aldrich), 1 mg/ml collagenase D (Roche), and 0.15 mg/ml
777 DNaseI, filtered through a 70 µm mesh. Homogenized sections were resuspended in 40% percoll, prior to
778 density centrifugation (1000 × g. 15 min at 20°C with low acceleration and no brake). The isolated cells
779 were washed with cold PBS and resuspended in PBS containing 1% BSA for direct cell surface staining.
780 Single-cell suspensions were stained with antibodies for 45 min on ice against CD45, CD11b, CD11c, Ly6C,
781 Ly6G, B220, CD3 and EpCAM (Biolegend). Stained cells were analyzed on a BD-LSRFortessa cytometer
782 and were analyzed with FlowJo software.

783

784 **Mucus proteomic analysis**

785 For proteome analyses isolated mucus samples were incubated overnight at 37°C in reduction buffer (6M
786 guanidinium hydrochloride, 0.1M Tris/HCl, pH 8.5, 5mM EDTA, 0.1 M DTT (Merck)) and soluble fraction
787 was added on top of a spin-filter (10 kDa, PALL, Port Washington, NY) for a filter-aided sample preparation
788 following a previous protocol³² where 6M GuHCl was used instead of urea. Proteins on the filters were
789 alkylated and subsequently digested for 4h with LysC (Wako, Richmond, VA) followed by an overnight
790 trypsin (Promega, Fitchburg, WI) digestion. Heavy peptides (SpikeTides TQL, JPT Peptide Technologies,
791 Berlin, Germany) for Muc2 absolute quantification (10 peptides, 100 fmol each³³ were added before
792 trypsin digestion. Peptides released from the filter after centrifugation were cleaned with StageTip C18
793 columns³⁴. NanoLC-MS/MS was performed on an EASY-nLC 1000 system (Thermo Fisher Scientific),
794 connected to a Q Exactive HF Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo Fisher Scientific)
795 through a nanoelectrospray ion source. Peptides were separated with an in-house packed reverse-phase

796 column (150 x 0.075 mm inner diameter, C18-AQ 3 μ m) by a 30 min gradient from 10 to 45% of buffer B
797 (A: 0.1% formic acid, B: 0.1% formic acid/80% acetonitrile) using a flow rate of 300 nl/min. Full mass
798 spectra were acquired from 350–1,600 m/z with resolution of 60,000 (m/z 200). Up to 15 most intense
799 peaks (charge state ≥ 2) were fragmented and tandem mass spectra were acquired with a resolution of
800 15,000 and 20 s dynamic exclusion. For absolute quantification a separate targeted mass spectrometry
801 method was used where only precursors and their fragments of the heavy and corresponding light
802 peptides were scanned with a resolution of 30,000. Proteins were identified with the MaxQuant program
803 (version 1.5.7.4³⁵) by searching against the mouse (downloaded 11.07.2018) UniProt protein database
804 supplemented with an in-house database containing all the mouse mucin sequences
805 (<http://www.medkem.gu.se/mucinbiology/databases/>). Searches were performed with full tryptic
806 specificity, maximum 2 missed cleavages, precursor tolerance of 20 ppm in the first search used for
807 recalibration, followed by 7 ppm for the main search and 0.5 Da for fragment ions. Carbamido-
808 methylation of cysteine was set to fixed modification and methionine oxidation and protein N-terminal
809 acetylation were set as variable modification. The required false discovery rate (FDR) was set to 1% both
810 for peptide and protein levels and the minimum required peptide length was set to six amino acids.
811 Proteins were quantified based on MaxQuant label-free quantification (LFQ) option using a minimum of
812 two peptides for quantification. Absolute quantification of Muc2 was performed with Skyline (version
813 4.2.0³⁶).

814

815 **Bacterial cultures**

816 *Akkermansia muciniphila* (ATCC BAA-835), *Akkermansia muciniphila* (ATCC BAA-2869), *Ruminococcus*
817 *torques* (ATCC 27756), *Lactobacillus gasseri* (ATCC 33323), *Prevotella melaninogenica* (ATCC 25845),
818 *Coprobacillus cateniformis* (DSM-15921), *Parabacteroides goldsteinii* (DSM-19448), *Lactobacillus murinus*
819 (DSM-100194), *Parabacteroides distasonis* (ATCC 8503), *Eisenbergiella tayi* (DSM-24404)
820 *Subdoligranulum variabile* (SDM-15176) were grown in chopped meat medium (BD 297307) under
821 anaerobic conditions (Coy Laboratory Products, 75% N₂, 20% CO₂, 5% H₂) in 37°C without shaking.
822 *Eggerthella lenta* (DSM-15644) was grown in chopped meat medium supplemented with 0.5% arginine.
823 All strains were validated for purity by whole-gene 16S sanger sequencing. WT and Δ nadA *E. coli* were
824 kindly provided by Professor Shimshon Belkin (Institute of Life Sciences, the Hebrew University, Jerusalem,
825 Israel), originally obtained from the “Keio collection³⁷” and were grown on LB media (WT) or LB
826 supplemented with 30 μ g/ml kanamycin (Δ nadA). To measure bacterial *in-vitro* nicotinamide secretion,
827 bacterial strains were grown in chopped meat medium until stationary phase, centrifuged and washed
828 twice with M9 minimal medium with trace elements and glucose (4 g/l) and resuspended in M9 for 3 hrs
829 under anaerobic conditions. Following centrifugation, 50 μ l of the supernatant was collected for targeted
830 nicotinamide measurements, and protein was extracted from the pellet using the BCA method: briefly:
831 bacterial pellets were homogenized in RIPA buffer containing protease inhibitors, incubated for 45 min in
832 4 °C and centrifuged for 20 min, 14,000 r.p.m., at 4 °C. Nicotinamide measurement in the media were
833 then normalized to the total protein level in each sample.

834

835 **Nucleic acid extraction**

836 *DNA purification*

837 Genomic DNA was purified using PowerMag Soil DNA isolation kit (Qiagen) optimized for Tecan
838 automated platform. For shotgun sequencing, Illumina libraries were prepared using Nextera DNA Samp

839 Prep kit (Illumina, FC-121-1031), according to manufacturer's protocol and sequenced using the Illumina
840 NextSeq platform with a read length of 80bp.

841

842 *RNA Purification*

843 Spinal cord samples were harvested from mice and snap-frozen in liquid nitrogen. Tissues were
844 homogenized in Tri Reagent (Bio-Lab). RNA was purified using standard chloroform extraction. Two
845 micrograms of total RNA were used to generate cDNA (HighCapacity cDNA Reverse Transcription kit;
846 Applied Biosystems).

847 Real-time PCR was performed using Kapa Sybr qPCR kit (Kapa Biosystems) on a Vii7 instrument (Applied
848 Biosystems). PCR conditions were 95 °C for 20 s, followed by 40 cycles of 95 °C for 3 s and 60 °C for 30 s.
849 Data were analyzed using the $\Delta\Delta C_t$ method with 16S serving as the reference housekeeping gene. 16S
850 cycles were assured to be insensitive to the experimental conditions.

851

852 **Nucleic acid processing and library preparation**

853 *16S qPCR Protocol for Quantification of Bacterial DNA*

854 DNA templates were diluted to 1 ng/ μ l before amplifications with the primer sets (indicated in Table I)
855 using the Fast SybrTMGreen Master Mix (ThermoFisher) in duplicates. Amplification conditions for
856 *Akkermansia muciniphila* were: Denaturation 95°C for 3 minutes, followed by 40 cycles of denaturation
857 95°C for 3 seconds; annealing 66°C for 30 seconds followed by meting curve. Amplification conditions for
858 total bacteria (16S rRNA) were: Denaturation 95°C for 3 minutes, followed by 40 cycles of denaturation
859 95°C for 3 seconds; annealing 60°C for 30 seconds followed by meting curve. Duplicates with >2 cycle
860 difference were excluded from analysis. The CT value for any sample not amplified after 40 cycles was
861 defined as 40 (threshold of detection).

862

863 **16S rDNA Sequencing**

864 For 16S amplicon pyrosequencing, PCR amplification was performed spanning the V3/4 region using the
865 primers 515F/806R of the 16S rDNA gene and subsequently sequenced using 2x250 bp paired-end
866 sequencing (Illumina MiSeq). Custom primers were added to Illumina MiSeq kit resulting in 253 bp
867 fragment sequenced following paired end joining to a depth of 110,998 \pm 66,946 reads (mean \pm SD).

868 Read1: TATGGTAATTGTGTGCCAGCMGCCGCGGTAA

869 Read2: AGTCAGTCAGCCGGACTACHVGGGTWTCTAAT

870 Index sequence primer: ATTAGAWACCCBDGTAGTCCGGCTGACTGACTATTAGAA

871

872 **Whole genome shotgun sequencing**

873 100 ng of purified DNA was sheared with a Covaris E220X sonicator. Illumina compatible libraries were
874 prepared as described³⁸, and sequenced on the Illumina NextSeq platform with a read length of 80bp to
875 a depth of 10M reads for human samples, 1M reads for AM treated mice samples and 5M reads for the
876 comparison between naïve WT and SOD1-Tg mice.

877

878 **RNA-Seq**

879 Ribosomal RNA was selectively depleted by RNaseH (New England Biolabs, M0297) according to a
880 modified version of a published method³⁹. Specifically, a pool of 50bp DNA oligos (25 nM, IDT, indicated
881 in Table II) that is complementary to murine rRNA18S and 28S, was resuspended in 75 μ l of 10 mM Tris

882 pH 8.0. Total RNA (100-1000 ng in 10 μ l H₂O) were mixed with an equal amount of rRNA oligo pool, diluted
883 to 2 μ l and 3 μ l 5x rRNA hybridization buffer (0.5 M Tris-HCl, 1 M NaCl, titrated with HCl to pH 7.4) was
884 added. Samples were incubated at 95°C for 2 minutes, then the temperature was slowly decreased
885 (-0.1°C/s) to 37°C. RNaseH enzyme mix (2 μ l of 10U RNaseH, 2 μ l 10 x RNaseH buffer, 1 μ l H₂O, total 5 μ l
886 mix) was prepared 5 minutes before the end of the hybridization and preheated to 37°C. The enzyme mix
887 was added to the samples when they reached 37°C and they were incubated at this temperature for 30
888 minutes. Samples were purified with 2.2x SPRI beads (AMPure XP, Beckmann Coulter) according to the
889 manufacturers' instructions. Residual oligos were removed with DNase treatment (ThermoFisher
890 Scientific, AM2238) by incubation with 5 μ l DNase reaction mix (1 μ l Turbo DNase, 2.5 μ l Turbo DNase 10
891 x buffer, 1.5 μ l H₂O) that was incubated at 37°C for 30 minutes. Samples were again purified with 2.2x
892 SPRI beads and suspended in 3.6 μ l priming mix (0.3 μ l random primers of New England BioLabs, E7420,
893 3.3 μ l H₂O). Samples were subsequently primed at 65°C for 5 minutes. Samples were then transferred to
894 ice and 2 μ l of the first strand mix was added for first strand cDNA synthesis (1 μ l 5x first strand buffer,
895 NEB E7420; 0.125 μ l RNase inhibitor, NEB E7420; 0.25 μ l ProtoScript II reverse transcriptase, NEB E7420;
896 and 0.625 μ l of 0.2 μ l/ml Actinomycin D, Sigma, A1410). The first strand synthesis and all subsequent
897 library preparation steps were performed using NEBNext Ultra Directional RNA Library Prep Kit for
898 Illumina (NEB, E7420) according to the manufacturers' instructions (all reaction volumes reduced to a
899 quarter).

900 **16S rDNA analysis**

901 Overlapping paired-end FASTQ files were matched and processed in a data curation pipeline implemented
902 in Qiime2 version 2018.4.0 (Qiime2)⁴⁰. Paired-end sequence data were demultiplexed according to sample
903 specific barcodes using Qiime2 demux-emp-paired. Trimming and amplicon sequence variant (ASV)
904 picking were carried out with the use of DADA2⁴¹. Alpha rarefaction curves were plotted using Qiime2
905 alpha-rarefaction and were used to set an appropriate subsampling depth for each comparison. Samples
906 were rarefied using Qiime2 feature-table rarefy⁴². Samples with a read depth lower than the relevant
907 subsampling depth were excluded from the analysis. ASV's were assigned with taxonomic annotations
908 using a Naïve-Bayes fitted classifier trained on August 2013, 97% identity Greengenes rRNA database⁴³.
909 Relative abundance tables were calculated using Qiime2 feature-table summarize-taxa. Ordination plots
910 were calculated from Unweighted and Weighted UniFrac distance matrix using principal coordinates
911 analysis (PCoA).

912

913 **Metagenomic analysis**

914 For metagenome analysis, metagenomic reads containing Illumina adapters and low-quality reads were
915 filtered and low-quality read edges were trimmed. Host DNA was detected by mapping with GEM⁴⁴ to
916 the human or mouse genome (hg19 or mm10 respectively) with inclusive parameters, and host reads
917 were removed. For SOD1-Tg vs. WT naïve mice metagenomes 5 million reads were subsampled, 1 million
918 reads for AM-treated mice and for humans 7-10 million reads. Relative abundances from metagenomic
919 sequencing were computed using MetaPhlAn2⁴⁵ with default parameters. MetaPhlAn relative abundances
920 were capped at a level of 5×10^{-4} . KO relative abundance was obtained by mapping to KEGG⁴⁶ bacterial
921 genes database using DIAMOND⁴⁷, considering only the first hit, and allowing e-value < 0.0001. The
922 relative abundance of a KO was determined as the sum of all reads mapped to bacterial genes associated
923 with that KO, divided by the total number of mapped reads in a sample. For mice samples, KO relative
924 abundance was obtained by first mapping to IGC, an integrated catalog of reference genes in the human

925 gut microbiome, and then summing the relative abundance of all the genes in each KO to obtain relative
926 abundance. KO relative abundances were capped at a level of 2×10^{-5} for mice and 2×10^{-7} for humans. Taxa
927 and KOs present in less than 10% of samples were discarded.

928

929 **Metabolites selection**

930 Using the top 12 significant serum metabolites altered by Abx in WT and SOD1-Tg mice, we first
931 downloaded all nucleotide sequences of KEGG genes with potential to synthesize or degrade the 12
932 metabolites. Next, we built a bowtie index of KEGG genes and mapped to it SOD1-Tg and WT metagenome
933 samples. Finally, we obtained all mapped reads and for every sample and KEGG gene, we report the
934 number of reads mapped to the KEGG gene and its mean score. Scores are as defined by bowtie2⁴⁸ and
935 range between 0 to -45, where 0 denotes perfect match.

936

937 **RNAseq analysis**

938 *Data pre-processing*

939 bcl files were converted to fastq and adaptor trimming was performed using bcl2fastq. Then, reads were
940 aligned to the mm10 reference genome (UCSC) using STAR (splice site aware alignment). Secondary
941 alignments and PCR/optical duplicates were removed using samtools view -h -F 256 -F 1024. Alignments
942 were binned to genes using htseq-count (htseq-count -a 5 -s reverse -r). Transcript integrity number (TIN)
943 medians were calculated using RSeQC. (tin.py.bed file: mm10 RefSeq.bed.gz downloaded from
944 https://sourceforge.net/projects/rseqc/files/BED/Mouse_Mus_musculus/)

945 *Differential gene expression*

946 For each comparison, genes with reads $\geq 10^{-4}$ out of total reads and expressed in at least fifth of a group
947 in each comparison were included in the analysis. Deseq2 models were fitted for each comparison
948 separately [design: counts ~ group + median (TIN)]. Differentially expressed genes were found using Wald-
949 test on Deseq2 objects. Heatmaps were created using the regularized log transformed data (rlog).

950 *gene set enrichment analysis*

951 For each gene, we calculated the following score out of its DESeq results: $-\log(\text{padj}) \text{ sign}(\log_2\text{FoldChange})$.
952 bulk.gsea function was used from liger package, with the [http://ge-lab.org/gskb/2-](http://ge-lab.org/gskb/2-MousePath/MousePath_GO_gmt.gmt)
953 [MousePath/MousePath_GO_gmt.gmt](http://ge-lab.org/gskb/2-MousePath/MousePath_GO_gmt.gmt) as our universe model.

954

955 **Non-targeted metabolomics**

956 Sera and cecal samples were collected, immediately frozen in liquid nitrogen and stored at -80°C . Sample
957 preparation and analysis was performed by Metabolon Inc. Samples were prepared using the automated
958 MicroLab STAR system (Hamilton). To remove protein, dissociated small molecules bound to protein or
959 trapped in the precipitated protein matrix, and to recover chemically diverse metabolites, proteins were
960 precipitated with methanol. The resulted extract was divided into five fractions: one for analysis by UPLC-
961 MS/MS with negative ion mode electrospray ionization, one for analysis by UPLC-MS/MS with positive ion
962 mode electrospray ionization, one for LC polar platform, one for analysis by GC-MS and one sample was
963 reserved for backup. Samples were placed briefly on a TurboVap (Zymark) to remove the organic solvent.
964 For LC, the samples were stored overnight under nitrogen before preparation for analysis. For GC, each
965 sample was dried under vacuum overnight before preparation for analysis.

966 *Data extraction and compound identification*

967 Raw data was extracted, peak-identified and QC processed using Metabolon's hardware and software.
968 Compound were identified by comparison to library entries of purified standards or recurrent unknown
969 entities.

970 *Metabolite quantification and data normalization*

971 Peaks were quantified using area-under-the-curve. For studies spanning multiple days, a data
972 normalization step was performed to correct variation resulting from instrument inter-day tuning
973 differences.

974

975 **Targeted metabolomics**

976 50ng/ml of D4-Nicotinamide (Cambridge Isotope Laboratories) were added to all samples as internal
977 standards. The samples (in 50% Methanol) were dried in a speed vac to blow off the methanol before
978 drying to completion in a lyophilizer. All samples were re-dissolved in 100 µl of 0.1% formic acid.

979 *Liquid Chromatography*

980 Liquid chromatography was performed on a Waters Acquity UPLC system. Metabolites were separated
981 on an Acquity HSS T3 column (2.1 × 150 mm, 1.8 µm particle size; Waters) at 40°C using a 10-min program.
982 Mobile phase consisted of (A) water and (B) acetonitrile each containing 0.1% formic acid. Gradient
983 conditions were: 0 to 1 min = 99.9% A 0.1% B; 1 to 6 min = 0.1% to 10.0% B; 6 to 7 min = 10% to 100% B;
984 7.0 to 7.2 min = 100% B; 7.2 to 10 min = 99.9% A, 0.1% B. Injection volume was 1.0 µl, and flow rate was
985 0.3 ml/min.

986 *Mass Spectrometry*

987 LC-MS/MS analysis was performed on a Waters Xevo triple quadrupole equipped with a Zspray ESI source.
988 MRM was performed in the positive ion mode. Other MS parameters included: desolvation temperature
989 at 600°C, desolvation gas flow at 900L/Hr, cone gas flow at 150L/Hr nebulizer pressure at 7 Bar, capillary
990 voltage (CV) at 2.53kV. The MRM transitions used were: (a) Nicotinamide: 123 > 78 and 123 > 80, CE 19,
991 13 V respectively and (b) D4-Nicotinamide 127 > 81 and 127 > 84, CE 19, 17 V respectively. Argon (0.10
992 mg/min) was used as collision gas. TargetLynx (Waters) was used for Qualitative and Quantitative analysis.
993

994 **Patients and control individuals**

995 *Human observational study*

996 The human observational study was approved by the Hadassah Medical Center Institutional Review Board
997 (IRB approval numbers HMO-16-0396) and Weizmann Institute of Science Bioethics and Embryonic Stem
998 Cell Research oversight committee (IRB approval numbers 365-1). Written informed consent was
999 obtained from all subjects.

1000

1001 *Exclusion and inclusion criteria (human observational study)*

1002 All subjects fulfilled the following inclusion criteria: males and females, aged 18-70, who are currently not
1003 following any interventional diet modification other than advice to avoid nutritional deficiencies and are
1004 able to provide informed consent. Exclusion criteria included: (i) pregnancy or fertility treatments; (ii)
1005 usage of antibiotics or antifungals within three months prior to participation; (iii) consumption of
1006 probiotics in any form within one month prior to participation, (iv) active inflammatory or neoplastic
1007 disease three years prior to enrollment; (v) chronic gastrointestinal disorder, including inflammatory
1008 bowel disease and celiac disease; (vi) myocardial infarction or cerebrovascular accident in the 6 months
1009 prior to participation; (vii) coagulation disorders; (viii) chronic immunosuppressive medication usage; (ix)

1010 pre-diagnosed type I or type II diabetes mellitus or treatment with anti-diabetic medication. None of the
1011 enrolled patients and controls reported of constipation or on taking constipation medications. One of the
1012 ALS patients had a chronic diagnosis of irritable bowel syndrome (IBS), another was diagnosed with
1013 asymptomatic PBC for 8 years prior to development of ALS, and was consuming Ursodecholic acid
1014 (1500mg per day). Two patients were diagnosed with chronic dyspepsia and one with reflux esophagitis.
1015 Two of them were chronically treated (for years) with proton pumps inhibitors. Adherence to inclusion
1016 and exclusion criteria was validated by medical doctors.

1017

1018 **Statistical Analysis**

1019 Data are expressed as mean \pm SEM. p values < 0.05 were considered significant (*p < 0.05 ; **p < 0.05 ;
1020 ***p < 0.005 ; ****p < 0.0005). Pairwise comparisons were performed using Student's t test. Mann-
1021 Whitney U test was used when the distribution was not known to be normal. Comparison between
1022 multiple groups was performed using ANOVA, and FDR correction was used to adjust for multiple
1023 comparisons. We analyzed the effect of Abx over time in control and SOD1-Tg mice by modeling neuro-
1024 phenotypical measurements (rotarod, grip test score and neurological score) as a function of time and
1025 treatment in a time-dependend manner using a linear regression:

1026 *Phenotype* \sim *time* + *time x treatment* + *time x genotype* + *time x treatment x genotype*

1027 where time is the day (60, 80, 100, 120 and 140), treatment (\pm Abx) and genotype (WT or SOD1-Tg) are
1028 binary indicators. Significance of treatment is then inferred by the p-value of the time x treatment
1029 predictor. For this analysis we used python statsmodels.api.ols version 0.8.0 statsmodels.

1030 Microbial abundance change over time was evaluated using linear regression:

1031 *OTU* \sim *time* + *time x genotype*

1032 The significance of genotype effecting OTU abundance was inferred by the p-value of the time x genotype
1033 predictor after 5% FDR correction for multiple OTUs.

1034 To analyze KOs of the nicotinamide and tryptophan metabolic pathways KO levels between groups were
1035 compared using Mann Whitney U ranksum test. For this analysis we use python
1036 stats.HigherLevelRanksum.directed_mannwhitneyu.

1037

1038